Comparative assessment of the treatment of type 2 diabetes mellitus

Annals of Saudi Medicine

Volumn 22, Issue 3-4, 2002, Pages 163-166

  Kokić, Slaven ^a   Radman, Maja ^a   Ĉapkun, Vesna ^a   Dovžak Kokić, Djurdja ^a   Tešanović, Sanda ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Biphasic insulin; Glimepiride; Glycemic control; Lispro; Metformin; NPH

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0036588479     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2002.163     Document Type: Article

References (38)

1. Gatling W, Houston AC, Hill RD. An epidemiologcial survey: the prevalence of diabetes mellitus in a typical English community. J R Coll Phys London 1985;4:248-50.
2. Neil HAW, Gatling W, Mather HM, et al. The Oxford Community Diabetes Study. Evidence for an increase in the prevalence of known diabetes in Great Britain. Diabet Med 1987;4:539-43.
3. Zimmet P. Type 2 (non-insulin dependent diabetes mellitus): an epidemiological review. Diabetologia 1982;22:399-411.
4. Roesler J, et al. Economic cost of diabetes mellitus. Minnesota, 1988. MMWR 1991;40:229.
5. American Diabetes Association. Direct and indirect costs of diabetes in the United States in 1987. Washington: American Diabetes Association, 1988.
6. British Diabetic Association. Diabetes in the United Kingdom. London: BDA, 1996.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
8. UKPD 33. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus. Lancet 1998; 352:837-53.
9. Panzram G. Mortality and survival in type 2 non-insulin dependent diabetes mellitus. Diabetologia 1987;30:123-31.
10. Klein R, Klein BE, Anderson S, Moss SE. Hypoglycaemic therapy in-patients diagnosed to have diabetes at 30 years of age. J Chron Dis 1984;37:159-65.
11. Birkland KI, Rishaung U, Hanssen KF, Vaaler S. NIDDM: a rapid progressive disease: results from a long-term, randomized, comparative study of insulin or sulphonylurea treatment. Diabetologia 1996;39:1629-33.
12. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimes in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389-6.
13. Claudi T, Jervell J. Insulin therapy in NIDDM: when and how to start. Diabetes News (Excerpta Medica) 1989;10:1-3.
14. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimes in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327: 1426-33.
15. Chow CC, Tsang LW, Sorensen JOP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18:307-14.
16. Van der Wal PS, Scheen AJ, Van Gaal L, Schmitt H, Heine RJ, Swin Study Group. Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents. Diabetes 1996;45(Suppl 2):286A. 56th Annual Meeting of the American Diabetes Association, San Francisco, USA, June, 1996.
17. Perriello G, Di Matteo G, Pamparelli S, Santamaria G, Picchio E, Bolli GB, et al. Metformin associated to insulin therapy for treatment of obese NIDDM (abstract). 16th International Diabetes Federation Congress. 20-25 July, 1997, Helsinki, Finland.
18. Barnett AH. Insulin in the management of type 2 diabetes. Diabetes Rev Intern 1996;5:12-4.
19. Yki-Järvinen Hannele. Advances in insulin therapy in NIDDM, Rev Intern 1996;5:10.
20. Peters JA, Davidson MB. Insulin plus sulphonylurea agents for treating type 2 diabetes. Ann Intern Med 1994; 115:45-53.
21. Pugh JA, Wagner MI, Sawyer G, et al. Is combination sulphonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992;15:953-9.
22. Landstedt-Hallin L, Adamson U, Amer P, et al. Comparison of bedtime NPH of pre-prandial regular insulin combined with glibenclamide in secondary sulphonylurea failure. Diabetes Care 1995;18:1183-6.
23. Clauson P, Karlander S, Steen L, Efendic S. Day-time glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a one-year follow up. Diabet Med 1996;13:471-7.
24. Berger W. Insulin therapy in the elderly type 2 diabetic patient. Diabetes Research and Clinical Practice 1988;(Suppl):S24-28.
25. Taylor R. Use of insulin in non-insulin-dependent diabetes. Diabetes Rev 1992;1:9-11.
26. O'Rahilly S. Secretory failure or insulin resistance: which comes first in NIDDM? Diabetes News (Excerpta Medica) 1988;9:1-3.
27. Bastyr EJ, Johnson ME, Trautmann ME, Anderson JHJ, Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;1:1703-14.
28. Müller G, Satoh Y, Geisen K. Extrapancreatic effects: a comparison between glimepiride and conventional sulphonylureas. Diabetes Res Clin Pract Suppl 1995;28:115-37.
29. Draeger KE. Long term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride: a double-blind comparison with glibenclamide. Horm Metab Res 1996;9:419-27.
30. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Domach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes. Diabetes Care 1986;9:129-33.
31. Trautmann EM, Johnson M, Anderson JH Jr., Bastyr EJ III. IOCE Study Group. Comparison of meal time insulin lispro (LP) versus bed-time NPH (NPH) after oral sulfonylurea (SU) failure (abstract). ADA 58th Annual Meeting and Scientific Sessions, June 1998, Chicago, USA.
32. Trautmann EM, Johnson M, Anderson JH Jr., Bastyr EJ III. IOCE Study Group. Insulin lispro in the therapy of sulfonylurea failure (abstract). Lilly Research Laboratories, Indianapolis, US. ADA 58th Annual Meeting and Scientific Sessions, June 1998, Chicago, USA.
33. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6 year study. Diabetes Res Clin Pract 1995;28:103-17.
34. Ducimetiere P, Eschwege E, Papoz L, Richard J, Claude G, Rosseling G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980;19:205-10.
35. Fontbonne A, Thibault N, Eschwege E, Ducimetiere P. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus. The Paris Prospective Study: 15-year follow-up. Diabetologia 1992;35:464-8.
36. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-41.
37. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care 1979;2:154-60.
38. 1c. Diabetes Care 2000;